430 related articles for article (PubMed ID: 30642290)
1. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
Bahig H; Aubin F; Stagg J; Gologan O; Ballivy O; Bissada E; Nguyen-Tan FP; Soulières D; Guertin L; Filion E; Christopoulos A; Lambert L; Tehfe M; Ayad T; Charpentier D; Jamal R; Wong P
BMC Cancer; 2019 Jan; 19(1):68. PubMed ID: 30642290
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Siu LL; Even C; Mesía R; Remenar E; Daste A; Delord JP; Krauss J; Saba NF; Nabell L; Ready NE; Braña I; Kotecki N; Zandberg DP; Gilbert J; Mehanna H; Bonomi M; Jarkowski A; Melillo G; Armstrong JM; Wildsmith S; Fayette J
JAMA Oncol; 2019 Feb; 5(2):195-203. PubMed ID: 30383184
[TBL] [Abstract][Full Text] [Related]
3. Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL; Haddad R; Even C; Tahara M; Dvorkin M; Ciuleanu TE; Clement PM; Mesia R; Kutukova S; Zholudeva L; Daste A; Caballero-Daroqui J; Keam B; Vynnychenko I; Lafond C; Shetty J; Mann H; Fan J; Wildsmith S; Morsli N; Fayette J; Licitra L
Ann Oncol; 2020 Jul; 31(7):942-950. PubMed ID: 32294530
[TBL] [Abstract][Full Text] [Related]
4. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
Schoenfeld JD; Giobbie-Hurder A; Ranasinghe S; Kao KZ; Lako A; Tsuji J; Liu Y; Brennick RC; Gentzler RD; Lee C; Hubbard J; Arnold SM; Abbruzzese JL; Jabbour SK; Uboha NV; Stephans KL; Johnson JM; Park H; Villaruz LC; Sharon E; Streicher H; Ahmed MM; Lyon H; Cibuskis C; Lennon N; Jhaveri A; Yang L; Altreuter J; Gunasti L; Weirather JL; Mak RH; Awad MM; Rodig SJ; Chen HX; Wu CJ; Monjazeb AM; Hodi FS
Lancet Oncol; 2022 Feb; 23(2):279-291. PubMed ID: 35033226
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Psyrri A; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Vasilyev A; Karpenko A; Dvorkin M; Hsieh CY; Thungappa SC; Segura PP; Vynnychenko I; Haddad R; Kasper S; Mauz PS; Baker V; He P; Evans B; Wildsmith S; Olsson RF; Yovine A; Kurland JF; Morsli N; Seiwert TY;
Ann Oncol; 2023 Mar; 34(3):262-274. PubMed ID: 36535565
[TBL] [Abstract][Full Text] [Related]
6. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
Antonia S; Goldberg SB; Balmanoukian A; Chaft JE; Sanborn RE; Gupta A; Narwal R; Steele K; Gu Y; Karakunnel JJ; Rizvi NA
Lancet Oncol; 2016 Mar; 17(3):299-308. PubMed ID: 26858122
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
Powles T; van der Heijden MS; Castellano D; Galsky MD; Loriot Y; Petrylak DP; Ogawa O; Park SH; Lee JL; De Giorgi U; Bögemann M; Bamias A; Eigl BJ; Gurney H; Mukherjee SD; Fradet Y; Skoneczna I; Tsiatas M; Novikov A; Suárez C; Fay AP; Duran I; Necchi A; Wildsmith S; He P; Angra N; Gupta AK; Levin W; Bellmunt J;
Lancet Oncol; 2020 Dec; 21(12):1574-1588. PubMed ID: 32971005
[TBL] [Abstract][Full Text] [Related]
8. A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer.
Lee NY; Riaz N; Wu V; Brinkman T; Tsai CJ; Zhi W; Fetten J; Ho A; Wong RJ; Ghossein R; Tuttle M; Fagin J; Pfister DG; Sherman E
Thyroid; 2022 Jul; 32(7):799-806. PubMed ID: 35521657
[No Abstract] [Full Text] [Related]
9. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi NA; Cho BC; Reinmuth N; Lee KH; Luft A; Ahn MJ; van den Heuvel MM; Cobo M; Vicente D; Smolin A; Moiseyenko V; Antonia SJ; Le Moulec S; Robinet G; Natale R; Schneider J; Shepherd FA; Geater SL; Garon EB; Kim ES; Goldberg SB; Nakagawa K; Raja R; Higgs BW; Boothman AM; Zhao L; Scheuring U; Stockman PK; Chand VK; Peters S;
JAMA Oncol; 2020 May; 6(5):661-674. PubMed ID: 32271377
[TBL] [Abstract][Full Text] [Related]
10. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
Fumet JD; Limagne E; Thibaudin M; Truntzer C; Bertaut A; Rederstorff E; Ghiringhelli F
BMC Cancer; 2020 Aug; 20(1):748. PubMed ID: 32778095
[TBL] [Abstract][Full Text] [Related]
11. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
Doki Y; Ueno M; Hsu CH; Oh DY; Park K; Yamamoto N; Ioka T; Hara H; Hayama M; Nii M; Komuro K; Sugimoto M; Tahara M
Cancer Med; 2022 Jul; 11(13):2550-2560. PubMed ID: 35611499
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Leighl NB; Redman MW; Rizvi N; Hirsch FR; Mack PC; Schwartz LH; Wade JL; Irvin WJ; Reddy SC; Crawford J; Bradley JD; Stinchcombe TE; Ramalingam SS; Miao J; Minichiello K; Herbst RS; Papadimitrakopoulou VA; Kelly K; Gandara DR
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34429332
[TBL] [Abstract][Full Text] [Related]
13. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
Pakkala S; Higgins K; Chen Z; Sica G; Steuer C; Zhang C; Zhang G; Wang S; Hossain MS; Nazha B; Beardslee T; Khuri FR; Curran W; Lonial S; Waller EK; Ramalingam S; Owonikoko TK
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428583
[TBL] [Abstract][Full Text] [Related]
14. Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
Han X; Zhang H; Sun K; Li J; Wu W; Liu K; Yu Z
Front Immunol; 2023; 14():1302840. PubMed ID: 38299153
[TBL] [Abstract][Full Text] [Related]
15. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma.
Fujiwara Y; Takahashi Y; Okada M; Kishimoto T; Kondo S; Fujikawa K; Hayama M; Sugeno M; Ueda S; Komuro K; Lanasa M; Nakano T
Oncologist; 2022 Sep; 27(9):e703-e722. PubMed ID: 35671201
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in biomarker-selected subgroups from the KESTREL study of durvalumab and tremelimumab in recurrent or metastatic head and neck squamous cell carcinoma.
Seiwert TY; Wildsmith S; Fayette J; Harrington K; Gillison M; Ahn MJ; Takahashi S; Weiss J; Machiels JP; Baxi S; Baker V; Evans B; Morsli N; Jill Walker ; Real K; L'Hernault A; Psyrri A
Cancer Immunol Immunother; 2024 Mar; 73(4):70. PubMed ID: 38430375
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Roussot N; Fumet JD; Limagne E; Thibaudin M; Hervieu A; Hennequin A; Zanetta S; Dalens L; Fourrier T; Galland L; Jacob P; Bertaut A; Rederstorff E; Chevalier C; Ghirardi S; Gilbert E; Khoukaz A; Martin E; Nicolet C; Quivrin M; Thibouw D; Vulquin N; Truc G; Rouffiac M; Ghiringhelli F; Mirjolet C
BMC Cancer; 2023 Nov; 23(1):1080. PubMed ID: 37946136
[TBL] [Abstract][Full Text] [Related]
18. Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial.
Bassetti MF; Morris BA; Sethakorn N; Lang JM; Schehr JL; Zhao SG; Morris ZS; Buehler D; Eickhoff JC; Harari PM; Traynor AM; Campbell TC; Baschnagel AM; Leal TA
Int J Radiat Oncol Biol Phys; 2024 Apr; 118(5):1481-1489. PubMed ID: 38072321
[TBL] [Abstract][Full Text] [Related]
19. Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Kim H; Park S; Jung HA; Lee SH; Park K; Ahn YC; Oh D; Ahn MJ
Cancer Res Treat; 2023 Oct; 55(4):1104-1112. PubMed ID: 37202212
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response.
Sundahl N; De Wolf K; Rottey S; Decaestecker K; De Maeseneer D; Meireson A; Goetghebeur E; Fonteyne V; Verbeke S; De Visschere P; Reynders D; Van Gele M; Brochez L; Ost P
J Transl Med; 2017 Jun; 15(1):150. PubMed ID: 28662677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
